|RAAS Marker||n||Events||Median Split∗||Continuous Variable†|
|Odds Ratio (95% CI)||p Value||Odds Ratio (95% CI)||p Value|
|PRA||358||72||2.83 (1.61–4.99)||0.0003||1.80 (1.40–2.31)||<0.0001|
|Aldosterone||369||74||2.33 (1.30–4.16)||0.0045||1.13 (1.03–1.24)||0.0098|
WRF = worsening renal function; other abbreviations as in Table 1.
↵∗ HR for change in RAAS activation measure ≥ median versus < median (PRA median = 1.058 ng/ml/h; aldosterone median = −0.95 pg/ml) from proportional hazards regression model adjusted for trial, baseline RAAS activation, and baseline ACE-I/ARB and aldosterone antagonist use.
↵† OR for 10-U increase in PRA and 100-U increase in aldosterone. Proportional hazards regression models were adjusted for trial, baseline RAAS activation, and ACE-I/ARB and aldosterone antagonist use.